NAN appears again in the AFR on page32 today under small cap biotechs. US FDA approval seen as the last hurdle for US distribution of the Trophon EPR, likely to happen before years end.Dont forget US distribution will be taken care of by the GE conglomerates health arm.This should be seen as a huge tick of approval for the companies product having an international company the size of GE representing NAN in the biggest potential market in the world.Broker covering NAN has $1:52 price target over the next 12 months,
NAN appears again in the AFR on page32 today under small cap...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.07 |
Change
-0.020(0.49%) |
Mkt cap ! $1.235B | |||
| Open | High | Low | Value | Volume |
| $4.06 | $4.13 | $4.06 | $2.405M | 588.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1855 | $4.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.09 | 2814 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
| NAN (ASX) Chart |